

# TRANSMITTAL FORM

|  |                           |                   |
|--|---------------------------|-------------------|
| <h1 style="text-align: center; margin: 0;">TRANSMITTAL<br/>FORM</h1> | Application Serial Number | 09/256,156        |
|  | Filing Date               | February 24, 1999 |
|  | First Named Inventor      | Gillies           |
|  | Group Art Unit            | 1646              |
|  | Examiner Name             | J. F. Murphy      |
|  | Attorney Docket No.       | LEX-003           |

**ENCLOSURES (check all that apply)**

|   |  |   |
|---|--|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form  | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553)                      | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interference |
| <input checked="" type="checkbox"/> Check Attached<br><input type="checkbox"/> Copy of Fee Transmittal Form   | <input type="checkbox"/> Formal Drawing(s)   | <input type="checkbox"/> Appeal Brief (in triplicate)                                 |
| <input type="checkbox"/> Amendment and Response   | <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal                                 | <input type="checkbox"/> Status Inquiry   |
| <input type="checkbox"/> Preliminary<br><input type="checkbox"/> After Final  |  | <input checked="" type="checkbox"/> Return Receipt Postcard                           |
| <input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Letter to Official Draftsperson including Drawings<br>[Total Sheets _____]   | <input type="checkbox"/> Associate Power of Attorney   | <input checked="" type="checkbox"/> Certificate of Hand Delivery                      |
|   | <input type="checkbox"/> Terminal Disclaimer   | <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8    |
| <input type="checkbox"/> Petition for Extension of Time   | <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application | <input type="checkbox"/> Additional Enclosure(s)<br><i>(please identify below)</i>    |
| <input checked="" type="checkbox"/> Information Disclosure Statement  | <input type="checkbox"/> Small Entity Statement  |   |
| <input checked="" type="checkbox"/> Form PTO-1449<br>003 GAN NY 00000 Copies of IDS<br>006 Citations (A2-A54; B7-B82; C100 00 00<br>C142)                   | <input type="checkbox"/> CD(s) for large table or computer program   |   |
| <input type="checkbox"/> Certified Copy of Priority Document(s)   | <input type="checkbox"/> Amendment After Allowance   |   |
| <input type="checkbox"/> Sequence Listing submission  | <input type="checkbox"/> Request for Certificate of Correction   |   |
| <input type="checkbox"/> Paper Copy/CD<br><input type="checkbox"/> Computer Readable Copy<br><input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Certificate of Correction (in duplicate)  |   |

05/02/2003 GANT NY 00000 Copies of IES  
01 FC: 1806 Citations (A2-A54;  
B7-B82; C1000 DP  
C142)

RECEIVED

MAY 05 2003

TECH CENTER 1600/2900

## CORRESPONDENCE ADDRESS

## SIGNATURE BLOCK

Direct all correspondence to: Patent Administrator  
Testa, Hurwitz & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110  
Tel. No.: (617) 248-7000  
Fax No.: (617) 248-7100

Date: April 29, 2003  
Reg. No. 41,418  
Tel. No.: (617) 248-7240  
Fax No.: (617) 248-7100




Respectfully submitted

Pat R.H. Wall  
Patrick R.H. Waller  
Attorney for Applicant  
Testa, Hurwitz & Thibeault, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110

**FEE TRANSMITTAL  
FY 2003**

|                           |                   |
|---------------------------|-------------------|
| <i>Complete if Known</i>  |                   |
| Application Serial Number | 09/256,156        |
| Filing Date               | February 24, 1999 |
| First Named Inventor      | Gillies           |
| Group Art Unit            | 1646              |
| Examiner Name             | J. F. Murphy      |
| Attorney Docket No.       | LEX-003           |

TECH CENTER 1600/2000  
RECEIVED  
MAY 1 2003

| <b>METHOD OF PAYMENT</b>   |                                       | <b>FEES CALCULATION (continued)</b>  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
|--|---------------------------------------|--|--------------------------|-------------------------|--|-----------------|----------|--|-------------------------------------|--|------------------|------|-------------------|----------|----------|------------------------|------|--|----------|---------|--------------|------|--|--|--|--------------|--|--|--|--|--|--|--|
| 1. <input checked="" type="checkbox"/> Payment Enclosed:<br><input checked="" type="checkbox"/> Check <input type="checkbox"/> Money Order <input type="checkbox"/> Other  |                                       | 3. ADDITIONAL FEES   |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| 2. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531.<br><input type="checkbox"/> Required Fees (copy of this sheet enclosed).<br><input checked="" type="checkbox"/> Additional fee required under 37 CFR 1.16 and 1.17.<br><input checked="" type="checkbox"/> Overpayment Credit.  |                                       | Large Entity<br>Fee (\$)   | Small Entity<br>Fee (\$) |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| 3. <input type="checkbox"/> Applicant claims small entity status.  |                                       | Fee Description  | Fee Paid                 |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| <b>FEES CALCULATION</b>  |                                       |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| 1. FILING FEE  |                                       |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| <table border="1"> <thead> <tr> <th colspan="2">Large Entity</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee (\$)</th> <th>Fee Description</th> </tr> </thead> <tbody> <tr> <td>750</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>330</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>160</td> <td>Provisional filing fee</td> <td></td> </tr> </tbody> </table>  |                                       |  |                          | Large Entity            |  | Fee Paid        | Fee (\$) | Fee Description  | 750                                 | Utility filing fee   |                  | 330  | Design filing fee |          | 160      | Provisional filing fee |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Large Entity   |                                       | Fee Paid   |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Fee (\$)   | Fee Description                       |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| 750  | Utility filing fee                    |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| 330  | Design filing fee                     |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| 160  | Provisional filing fee                |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Number Filed   | Number Extra                          | Rate   | Amount                   |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Total Claims   | - 20 =                                | x \$ 18.00 =   |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Independent Claims   | - 3 =                                 | x \$ 84.00 =   |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| <input type="checkbox"/> Multiple Dependent Claim(s), if any   |                                       | \$280.00 =   |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| TOTAL:<br>SMALL ENTITY DISCOUNT:<br>SUBTOTAL (1) (\$ 0.00)   |                                       |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| <table border="1"> <thead> <tr> <th colspan="5">2. AMENDMENT CLAIM FEES</th> </tr> <tr> <th>Claims<br/>Remaining<br/>After Amend.</th> <th>Highest No.<br/>Previously<br/>Paid For</th> <th>Present<br/>Extra</th> <th>Rate</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>Total 13</td> <td>- 44 = 0</td> <td>x \$ 18.00 =</td> <td>0.00</td> <td></td> </tr> <tr> <td>Indep. 3</td> <td>- 4 = 0</td> <td>x \$ 84.00 =</td> <td>0.00</td> <td></td> </tr> <tr> <td colspan="2"><input type="checkbox"/> First Presentation of Multiple Dep. Claim</td> <td>+ \$280.00 =</td> <td></td> <td></td> </tr> <tr> <td colspan="2" style="text-align: center;">TOTAL:<br/>SMALL ENTITY DISCOUNT:<br/>SUBTOTAL (2) (\$ 0.00)</td> <td></td> <td></td> <td></td> </tr> </tbody> </table>   |                                       |  |                          | 2. AMENDMENT CLAIM FEES |  |                 |          |  | Claims<br>Remaining<br>After Amend. | Highest No.<br>Previously<br>Paid For  | Present<br>Extra | Rate | Fee Paid          | Total 13 | - 44 = 0 | x \$ 18.00 =           | 0.00 |  | Indep. 3 | - 4 = 0 | x \$ 84.00 = | 0.00 |  | <input type="checkbox"/> First Presentation of Multiple Dep. Claim |  | + \$280.00 = |  |  | TOTAL:<br>SMALL ENTITY DISCOUNT:<br>SUBTOTAL (2) (\$ 0.00) |  |  |  |  |
| 2. AMENDMENT CLAIM FEES  |                                       |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Claims<br>Remaining<br>After Amend.  | Highest No.<br>Previously<br>Paid For | Present<br>Extra   | Rate                     | Fee Paid                |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Total 13   | - 44 = 0                              | x \$ 18.00 =   | 0.00                     |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Indep. 3   | - 4 = 0                               | x \$ 84.00 =   | 0.00                     |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| <input type="checkbox"/> First Presentation of Multiple Dep. Claim   |                                       | + \$280.00 =   |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| TOTAL:<br>SMALL ENTITY DISCOUNT:<br>SUBTOTAL (2) (\$ 0.00)   |                                       |  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| <table border="1"> <thead> <tr> <th colspan="2">CORRESPONDENCE ADDRESS</th> <th colspan="2">SIGNATURE BLOCK</th> </tr> </thead> <tbody> <tr> <td colspan="2">Direct all correspondence to:<br/>Patent Administrator<br/>Testa, Hurwitz &amp; Thibeault, LLP<br/>High Street Tower-125 High Street<br/>Boston, MA 02110<br/>Tel. No.: (617) 248-7000<br/>Fax No.: (617) 248-7100</td> <td colspan="2">                     Respectfully submitted,<br/> <br/>                     Patrick R.H. Waller<br/>                     Attorney for the Applicants<br/>                     Testa, Hurwitz &amp; Thibeault, LLP<br/>                     High Street Tower-125 High Street<br/>                     Boston, MA 02110                 </td> </tr> </tbody> </table> |                                       |  |                          | CORRESPONDENCE ADDRESS  |  | SIGNATURE BLOCK |          | Direct all correspondence to:<br>Patent Administrator<br>Testa, Hurwitz & Thibeault, LLP<br>High Street Tower-125 High Street<br>Boston, MA 02110<br>Tel. No.: (617) 248-7000<br>Fax No.: (617) 248-7100 |                                     | Respectfully submitted,<br><br>Patrick R.H. Waller<br>Attorney for the Applicants<br>Testa, Hurwitz & Thibeault, LLP<br>High Street Tower-125 High Street<br>Boston, MA 02110 |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| CORRESPONDENCE ADDRESS   |                                       | SIGNATURE BLOCK  |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |
| Direct all correspondence to:<br>Patent Administrator<br>Testa, Hurwitz & Thibeault, LLP<br>High Street Tower-125 High Street<br>Boston, MA 02110<br>Tel. No.: (617) 248-7000<br>Fax No.: (617) 248-7100   |                                       | Respectfully submitted,<br><br>Patrick R.H. Waller<br>Attorney for the Applicants<br>Testa, Hurwitz & Thibeault, LLP<br>High Street Tower-125 High Street<br>Boston, MA 02110 |                          |                         |  |                 |          |  |                                     |  |                  |      |                   |          |          |                        |      |  |          |         |              |      |  |  |  |              |  |  |  |  |  |  |  |

PATENT  
Attorney Docket No. LEX-003  
400614


RECEIVED  
TECH CENTER 1600/2900  
MAY - 1 PM 1:23  
2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et al.  
SERIAL NO.: 09/256,156 GROUP NO.: 1646  
FILING DATE: February 24, 1999 EXAMINER: J. F. Murphy  
TITLE: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being hand delivered to Group Art Unit No. 1646 at the United States Patent and Trademark Office in 3 boxes addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, to the attention of Examiner Joseph F. Murphy, on this 1<sup>st</sup> day of May, 2003.



Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RECEIVED

MAY 05 2003

Sir:

  
TECH CENTER 1600/2900

Submitted herewith is/are:

Transmittal Form (1 page); Fee Transmittal Form (1 page); Supplemental Information Disclosure Statement (2 pages); Supplemental Form PTO-1449 (15 pages); copies of references A2-A54, B7-B82, & C10-C142; a check in the amount of \$180.00; and a return receipt postcard.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Gillies et. al

SERIAL NO.: 09/256,156 GROUP NO.: 1646

FILING DATE: February 24, 1999 EXAMINER: J. F. Murphy

TITLE: Enhancing the Circulating Half-Life of Antibody-Based Fusion Proteins

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RECEIVED  
TECH CENTER 1600/2900

03 MAY - 1 PM 1:23

**RECEIVED**

MAY 05 2003

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

TECH CENTER 1600/2900

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filng date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
  - the requisite Statement is below, **OR**
  - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or


(3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**

the requisite Statement is below, **AND**

the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Patrick R.H. Waller, Ph.D.

Attorney for Applicant(s)

Testa, Hurwitz, & Thibeault, LLP

High Street Tower

125 High Street

Boston, Massachusetts 02110

Date: April 29, 2003  
Reg. No. 41,418

Tel. No.: (617) 248-7240  
Fax No.: (617) 248-7100

2614555

RECEIVED  
TECH CENTER 1600/2900  
03 MAY -1 PM 1:23

|  |  |                                |  |
|--|--|--------------------------------|--|
| FORM PTO - 1449                                  |  | ATTORNEY DOCKET NO.: LEX-003   |  |
| SUPPLEMENTAL INFORMATION<br>DISCLOSURE STATEMENT |  | APPLICANT(S): Gillies et al.   |  |
|  |  | SERIAL NO.: 09/256,156         |  |
|  |  | FILING DATE: February 24, 1999 |  |
|  |  | GROUP: 1646                    |  |

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME             | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|------------------|-------|--------------|-------------------------------|
|                | A2  | 07/348,237         | 5/5/89   | Rosenblum et al. |       |              |                               |
|                | A3  | 4,196,265          | 4/1/80   | Koprowski et al. |       |              |                               |
|                | A4  | 4,469,797          | 9/4/84   | Albarella        |       |              |                               |
|                | A5  | 4,676,980          | 6/30/87  | Segal et al.     |       |              |                               |
|                | A6  | 4,816,567          | 3/28/89  | Cabilly et al.   |       |              |                               |
|                | A7  | 4,946,778          | 8/7/90   | Ladner et al.    |       |              | RECEIVED                      |
|                | A8  | 5,073,627          | 12/17/91 | Curtis et al.    |       |              | MAY 05 2003                   |
|                | A9  | 5,114,711          | 5/19/92  | Bell et al.      |       |              |                               |
|                | A10 | 5,116,964          | 5/26/92  | Capon et al.     |       |              | TECH CENTER 1600/2900         |
|                | A11 | 5,199,942          | 4/6/93   | Gillis           |       |              |                               |
|                | A12 | 5,225,538          | 7/6/93   | Capon et al.     |       |              |                               |
|                | A13 | 5,225,539          | 7/6/93   | Winter           |       |              |                               |
|                | A14 | 5,258,498          | 11/2/93  | Huston et al..   |       |              |                               |
|                | A15 | 5,314,995          | 5/24/94  | Fell, Jr. et al. |       |              |                               |
|                | A16 | 5,349,053          | 9/20/94  | Landolfi         |       |              |                               |
|                | A17 | 5,359,035          | 10/25/94 | Habermann        |       |              |                               |
|                | A18 | 5,514,582          | 5/7/96   | Capon et al.     |       |              |                               |
|                | A19 | 5,538,866          | 7/23/96  | Israeli et al.   |       |              |                               |
|                | A20 | 5,541,087          | 7/30/96  | Lo et al.        |       |              |                               |
|                | A21 | 5,543,297          | 8/6/96   | Cromlish, et al. |       |              |                               |
|                | A22 | 5,552,524          | 09/03/96 | Basinski et al.  |       |              |                               |
|                | A23 | 5,585,089          | 12/17/96 | Queen et al.     |       |              |                               |
|                | A24 | 5,609,846          | 3/11/97  | Goldenberg       |       |              |                               |
|                | A25 | 5,639,725          | 6/17/97  | O'Reilly et al.  |       |              |                               |
|                | A26 | 5,650,150          | 7/22/97  | Gillies          |       |              |                               |
|                | A27 | 5,650,492          | 7/22/97  | Gately, et al.   |       |              |                               |
|                | A28 | 5,667,776          | 9/16/97  | Zimmerman et al. |       |              |                               |
| EXAMINER       |     |                    |          | DATE CONSIDERED  |       |              |                               |

|  |  |  |  |                                |  |             |  |
|--|--|--|--|--------------------------------|--|-------------|--|
| FORM PTO - 1449                                  |  |  |  | ATTORNEY DOCKET NO.: LEX-003   |  |             |  |
| SUPPLEMENTAL INFORMATION<br>DISCLOSURE STATEMENT |  |  |  | APPLICANT(S): Gillies et al.   |  |             |  |
|  |  |  |  | SERIAL NO.: 09/256,156         |  |             |  |
|  |  |  |  | FILING DATE: February 24, 1999 |  | GROUP: 1646 |  |

## U.S. PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | NAME              | CLASS | SUB<br>CLASS | FILING DATE IF<br>APPROPRIATE |
|----------------|-----|--------------------|----------|-------------------|-------|--------------|-------------------------------|
|                | A29 | 5,691,309          | 11/25/97 | Basinski et al.   |       |              |                               |
|                | A30 | 5,709,859          | 1/20/98  | Aruffo et al.     |       |              |                               |
|                | A31 | 5,719,266          | 02/17/98 | DiMarchi et al.   |       |              |                               |
|                | A32 | 5,723,125          | 3/3/98   | Chang et al.      |       |              |                               |
|                | A33 | 5,726,044          | 3/10/98  | Lo et al.         |       |              |                               |
|                | A34 | 5,728,552          | 3/17/98  | Fujisawa et al.   |       |              |                               |
|                | A35 | 5,733,876          | 3/31/98  | O'Reilly et al.   |       |              |                               |
|                | A36 | 5,756,461          | 05/26/98 | Stephens          |       |              |                               |
|                | A37 | 5,759,551          | 6/2/98   | Ladd et al.       |       |              |                               |
|                | A38 | 5,770,195          | 6/23/98  | Hudziak et al.    |       |              | MAY 05 2003                   |
|                | A39 | 5,800,810          | 9/1/98   | Doyle et al.      |       |              |                               |
|                | A40 | 5,827,516          | 10/27/98 | Urban et al.      |       |              |                               |
|                | A41 | 5,837,682          | 11/17/98 | Folkman et al.    |       |              |                               |
|                | A42 | 5,843,423          | 12/1/98  | Lyman et al.      |       |              |                               |
|                | A43 | 5,854,205          | 12/29/98 | O'Reilly et al.   |       |              |                               |
|                | A44 | 5,858,347          | 1/12/99  | Bauer et al.      |       |              |                               |
|                | A45 | 5,885,795          | 3/23/99  | O'Reilly et al.   |       |              |                               |
|                | A46 | 5,886,178          | 3/23/99  | Allen et al.      |       |              |                               |
|                | A47 | 5,994,126          | 11/30/99 | Steinman et al.   |       |              |                               |
|                | A48 | 6,080,409          | 6/27/00  | Laus et al.       |       |              |                               |
|                | A49 | 6,086,875          | 7/11/00  | Blumberg et al.   |       |              |                               |
|                | A50 | 6,100,387          | 8/8/00   | Herrmann et al.   |       |              |                               |
|                | A51 | 6,169,070          | 1/2/01   | Chen et al.       |       |              |                               |
|                | A52 | 6,171,588          | 1/9/01   | Carron et al.     |       |              |                               |
|                | A53 | 6,277,375 B1       | 8/21/01  | Ward              |       |              |                               |
|                | A54 | 6,406,689 B1       | 6/18/02  | Falkenberg et al. |       |              |                               |

EXAMINER

DATE CONSIDERED

RECEIVED

MAY 05 2003  
TECH CENTER 1600/2900

| FORM PTO - 1449                                  |     |                    |          | ATTORNEY DOCKET NO.: LEX-003               |                 |              |                    |   |                          |
|--|-----|--------------------|----------|--|-----------------|--------------|--------------------|---|--------------------------|
| SUPPLEMENTAL INFORMATION<br>DISCLOSURE STATEMENT |     |                    |          | APPLICANT(S): Gillies et al.               |                 |              |                    |   |                          |
|  |     |                    |          | SERIAL NO.: 09/256,156                     |                 |              |                    |   |                          |
|  |     |                    |          | FILING DATE: February 24, 1999 GROUP: 1646 |                 |              |                    |   |                          |
| FOREIGN PATENT DOCUMENTS                         |     |                    |          |  |                 |              |                    |   |                          |
| EXAM.<br>INIT.                                   |     | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE                            | CLASS           | SUB<br>CLASS | FILIN<br>G<br>DATE | ABSTRACT ONLY   | ENGLISH<br>LANG<br>(Y/N) |
|  | B7  | 0 158 198          | 10/16/85 | EP   |                 |              |                    |   | Y                        |
|  | B8  | 0 211 769          | 2/25/87  | EP   |                 |              |                    |   | Y                        |
|  | B9  | 0 256 714          | 2/24/88  | EP   |                 |              |                    | <i>RECEIVED<br/>MAY 05 2003<br/>TECH CENTER 1600/2900</i> | Y                        |
|  | B10 | 0 294 703          | 12/14/88 | EP   |                 |              |                    |   | Y                        |
|  | B11 | 0 308 936          | 3/29/89  | EP   |                 |              |                    |   | Y                        |
|  | B12 | 0 314 317          | 5/3/89   | EP   |                 |              |                    |   | Y                        |
|  | B13 | 0 319 012          | 6/7/89   | EP   |                 |              |                    |   | Y                        |
| 9  | B14 | 0 326 120          | 4/15/98  | EP   |                 |              |                    |   | Y                        |
|  | B15 | 0 350 230          | 1/10/90  | EP   |                 |              |                    |   | Y                        |
|  | B16 | 0 375 562          | 6/27/90  | EP   |                 |              |                    |   | Y                        |
|  | B17 | 0 396 387          | 11/7/90  | EP   |                 |              |                    |   | Y                        |
|  | B18 | 0 439 095          | 7/31/91  | EP   |                 |              |                    |   | Y                        |
|  | B19 | 0 511 747          | 11/4/92  | EP   |                 |              |                    |   | Y                        |
|  | B20 | 0 601 043          | 11/25/98 | EP   |                 |              |                    |   | Y                        |
|  | B21 | 0 706 799          | 4/17/96  | EP   |                 |              |                    |   | Y                        |
|  | B22 | 0 790 309          | 8/20/97  | EP   |                 |              |                    |   | Y                        |
|  | B23 | 21725/88           | 3/23/89  | AU   |                 |              |                    |   | Y                        |
|  | B24 | 93100115.3         | 7/14/93  | CN   |                 |              |                    | B78 is English abstract                                   | N                        |
|  | B25 | 37 12985           | 11/3/88  | DE   |                 |              |                    | B79 is English abstract;<br>A50 is English counterpart    | N                        |
|  | B26 | 2 292 382          | 2/21/96  | GB   |                 |              |                    |   | Y                        |
|  | B27 | 63-267278          | 11/4/88  | JP   |                 |              |                    | B80 is English abstract                                   | N                        |
|  | B28 | 63-267296          | 11/4/88  | JP   |                 |              |                    | B81 is English abstract;<br>B82 is English counter part   | N                        |
|  | B29 | WO 86/01533        | 3/13/86  | PCT  |                 |              |                    |   | Y                        |
| EXAMINER   |     |                    |          |  | DATE CONSIDERED |              |                    |   |                          |

|                          |  |  |  |                                |  |  |  |  |  |
|--------------------------|--|--|--|--------------------------------|--|--|--|--|--|
| FORM PTO - 1449          |  |  |  | ATTORNEY DOCKET NO.: LEX-003   |  |  |  |  |  |
| SUPPLEMENTAL INFORMATION |  |  |  | APPLICANT(S): Gillies et al.   |  |  |  |  |  |
| DISCLOSURE STATEMENT     |  |  |  | SERIAL NO.: 09/256,156         |  |  |  |  |  |
|                          |  |  |  | FILING DATE: February 24, 1999 |  |  |  |  |  |
|                          |  |  |  | GROUP: 1646                    |  |  |  |  |  |

RECEIVED  
MAY 05 2003  
TECH CENTER  
600/2900

## FOREIGN PATENT DOCUMENTS

| EXAM.<br>INIT. |     | DOCUMENT<br>NUMBER | DATE     | COUNTRY<br>CODE | CLASS | SUB<br>CLASS | FILIN<br>G<br>DATE | ABSTRACT<br>ONLY       | ENGLISH<br>LANG<br>(Y/N) |
|----------------|-----|--------------------|----------|-----------------|-------|--------------|--------------------|------------------------|--------------------------|
|                | B30 | WO 88/00052        | 1/14/88  | PCT             |       |              |                    |                        | Y                        |
|                | B31 | WO 88/09344        | 12/1/88  | PCT             |       |              |                    |                        | Y                        |
|                | B32 | WO 89/02922        | 4/6/89   | PCT             |       |              |                    |                        | Y                        |
|                | B33 | WO 89/09620        | 10/19/89 | PCT             |       |              |                    | Abstract in<br>English | N                        |
|                | B34 | WO 90/03801        | 4/19/90  | PCT             |       |              |                    |                        | Y                        |
|                | B35 | WO 91/00360        | 1/10/91  | PCT             |       |              |                    |                        | Y                        |
|                | B36 | WO 91/04329        | 04/04/91 | PCT             |       |              |                    |                        | Y                        |
|                | B37 | WO 91/08298        | 6/13/91  | PCT             |       |              |                    |                        | Y                        |
|                | B38 | WO 91/13166        | 9/5/91   | PCT             |       |              |                    |                        | Y                        |
|                | B39 | WO 91/14438        | 10/3/91  | PCT             |       |              |                    |                        | Y                        |
|                | B40 | WO 92/02240        | 2/20/92  | PCT             |       |              |                    |                        | Y                        |
|                | B41 | WO 92/08801        | 5/29/92  | PCT             |       |              |                    |                        | Y                        |
|                | B42 | WO 92/16562        | 10/1/92  | PCT             |       |              |                    |                        | Y                        |
|                | B43 | WO 93/03157        | 2/18/93  | PCT             |       |              |                    |                        | Y                        |
|                | B44 | WO 93/10229        | 5/27/93  | PCT             |       |              |                    |                        | Y                        |
|                | B45 | WO 95/21258        | 8/10/95  | PCT             |       |              |                    |                        | Y                        |
|                | B46 | WO 95/28427        | 10/26/95 | PCT             |       |              |                    |                        | Y                        |
|                | B47 | WO 95/31483        | 11/23/95 | PCT             |       |              |                    |                        | Y                        |
|                | B48 | WO 96/04388        | 02/15/96 | PCT             |       |              |                    |                        | Y                        |
|                | B49 | WO 96/05309        | 2/22/96  | PCT             |       |              |                    |                        | Y                        |
|                | B50 | WO 96/08570        | 3/21/96  | PCT             |       |              |                    |                        | Y                        |
|                | B51 | WO 96/31526        | 10/10/96 | PCT             |       |              |                    |                        | Y                        |
|                | B52 | WO 97/00317        | 1/3/97   | PCT             |       |              |                    |                        | Y                        |

EXAMINER

DATE CONSIDERED

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |                    |             |                 | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999      GROUP: 1646 |                 |                |                  |                          |  |
|--|--------------------|-------------|-----------------|---|-----------------|----------------|------------------|--------------------------|--|
| <b>FOREIGN PATENT DOCUMENTS</b>  |                    |             |                 |   |                 |                |                  |                          |  |
| EXAM.<br>INIT.   | DOCUMENT<br>NUMBER | DATE        | COUNTRY<br>CODE | CLASS   | SUB<br>CLASS    | FILING<br>DATE | ABSTRACT<br>ONLY | ENGLISH<br>LANG<br>(Y/N) |  |
|  | B53                | WO 97/15666 | 5/1/97          | PCT   |                 |                |                  | Y                        |  |
|  | B54                | WO 97/24137 | 7/10/97         | PCT   |                 |                |                  | Y                        |  |
|  | B55                | WO 97/24440 | 7/10/97         | PCT   |                 |                |                  | Y                        |  |
|  | B56                | WO 97/26335 | 7/24/97         | PCT   |                 |                |                  | Y                        |  |
|  | B57                | WO 97/30089 | 8/21/97         | PCT   |                 |                |                  | Y                        |  |
|  | B58                | WO 97/33619 | 9/18/97         | PCT   |                 |                |                  | Y                        |  |
|  | B59                | WO 97/34631 | 9/25/97         | PCT   |                 |                |                  | Y                        |  |
|  | B60                | WO 98/00127 | 1/8/98          | PCT   |                 |                |                  | Y                        |  |
|  | B61                | WO 98/06752 | 2/19/98         | PCT   |                 |                |                  | Y                        |  |
|  | B62                | WO 98/28427 | 7/2/98          | PCT   |                 |                |                  | Y                        |  |
|  | B63                | WO 98/30706 | 7/16/98         | PCT   |                 |                |                  | Y                        |  |
|  | B64                | WO 98/46257 | 10/22/98        | PCT   |                 |                |                  | Y                        |  |
|  | B65                | WO 98/59244 | 12/30/98        | PCT   |                 |                |                  | Y                        |  |
|  | B66                | WO 99/02709 | 01/21/99        | PCT   |                 |                |                  | Y                        |  |
|  | B67                | WO 99/03887 | 01/28/99        | PCT   |                 |                |                  | Y                        |  |
|  | B68                | WO 99/29732 | 6/17/99         | PCT   |                 |                |                  | Y                        |  |
|  | B69                | WO 99/43713 | 9/2/99          | PCT   |                 |                |                  | Y                        |  |
|  | B70                | WO 99/52562 | 10/21/99        | PCT   |                 |                |                  | Y                        |  |
|  | B71                | WO 99/53958 | 10/28/99        | PCT   |                 |                |                  | Y                        |  |
|  | B72                | WO 99/62944 | 12/09/99        | PCT   |                 |                |                  | Y                        |  |
|  | B73                | WO 00/11033 | 3/2/00          | PCT   |                 |                |                  | Y                        |  |
|  | B74                | WO 00/34317 | 06/15/00        | PCT   |                 |                |                  | Y                        |  |
|  | B75                | WO 00/40615 | 7/13/00         | PCT   |                 |                |                  | Y                        |  |
| EXAMINER   |                    |             |                 |   | DATE CONSIDERED |                |                  |                          |  |

| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  |   |          |                 | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999 |              |                |                            |                          |
|--|--|---|----------|-----------------|--|--------------|----------------|----------------------------|--------------------------|
| <b>FOREIGN PATENT DOCUMENTS</b>  |  |   |          |                 |  |              |                |                            |                          |
| EXAM.<br>INIT.   |  | DOCUMENT<br>NUMBER  | DATE     | COUNTRY<br>CODE | CLASS  | SUB<br>CLASS | FILING<br>DATE | ABSTRACT<br>ONLY           | ENGLISH<br>LANG<br>(Y/N) |
|  | B76  | WO 00/69913   | 11/23/02 | PCT             |  |              |                |                            | Y                        |
|  | B77  | WO 01/07081   | 2/1/01   | PCT             |  |              |                |                            | Y                        |
|  | B78  | 93100115.3  | 7/14/93  | CN              |  |              |                | English abstract of B24    | Y                        |
|  | B79  | 37 12985  | 11/3/88  | DE              |  |              |                | English abstract of B25    | Y                        |
|  | B80  | 63-267278   | 11/4/88  | JP              |  |              |                | English abstract of B27    | Y                        |
|  | B81  | 63-267296   | 11/4/88  | JP              |  |              |                | English abstract of B28    | Y                        |
|  | B82  | 0 237 019   | 9/16/87  | EP              |  |              |                | English counterpart of B28 | Y                        |
| EXAM.<br>INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |   |          |                 |  |              |                |                            |                          |
|  | C10  | Abaza et al., (1992) "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization" <u>Journal of Protein Chemistry</u> , Vol. 11, No. 5: pp. 433-444.                       |          |                 |  |              |                |                            |                          |
|  | C11  | Abstract XP-002116766, (1996) "Prostaglandins, their inhibitors and cancer" <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , Vol. 54, No. 2, pp. 83-94.  |          |                 |  |              |                |                            |                          |
|  | C12  | Arenberg et al. (1996) "Interferon- $\gamma$ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , Vol. 184, pp. 981-992.                                      |          |                 |  |              |                |                            |                          |
|  | C13  | Bacha et al., (1988). "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein", <u>J. Experimental Medicine</u> , Vol. 167, pp. 612-622   |          |                 |  |              |                |                            |                          |
|  | C14  | Bachelot et al., (March 1998) "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo", <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , Vol. 39, pp. 271, Abstract #1856. |          |                 |  |              |                |                            |                          |
|  | C15  | Barnett et al. (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.   |          |                 |  |              |                |                            |                          |
|  | C16  | Baselga, et al (1998) "Recombinant Humanized Anti-HER2 Antibody (Herceptin <sup>TM</sup> ) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/neu Overexpressing Human Breast Cancer Xenografts." <u>Cancer Research</u> , Vol. 58, pp. 2825-2831.              |          |                 |  |              |                |                            |                          |
| EXAMINER   |  |   |          |                 | DATE CONSIDERED  |              |                |                            |                          |

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900  
GROUNDED

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999<br>GROUP: 1646  |
|--|--|--|
| EXAM.<br>INIT.   | OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication) |  |
|  | C17  | Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , Vol. 5, No. 12, pp. 4259-4263.  |
|  | C18  | Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 2702-2707.  |
|  | C19  | Beutler et al., (1988) "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator", <u>Ann. Rev. Biochem.</u> , Vol. 57, pp. 505-518.   |
|  | C20  | Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins" <u>Cancer Research</u> , Vol. 45, pp. 1214-1221.   |
|  | C21  | Boehm et al. (1997) "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Letters to Nature</u> , Vol. 390, pp. 404-407.  |
|  | C22  | Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , Vol. 252, pp. 190-194.   |
|  | C23  | Brooks et al. (1994), "Integrin $\alpha_5\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , Vol. 79, pp. 1157-1164.   |
|  | C24  | Burgess et al., (1990), "Possible Dissociation of the heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , Vol. 111, pp. 2129-2138. |
|  | C25  | Canfield et al. (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , Vol. 173, No. 6, pp. 1483-1491.  |
|  | C26  | Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , Vol. 271, No. 46, pp. 29461-29467.  |
|  | C27  | Cao et al. (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 36, pp. 22924-22928.   |
|  | C28  | Capon et al. (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , Vol. 337, pp. 525-531.   |
|  | C29  | Chan et al., (1991) "Induction of Interferon $\gamma$ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.   |
|  | C30  | Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , Vol. 5, pp. 385-90.  |
|  | C31  | Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to <i>Pseudomonas</i> exotoxin" <u>Nature</u> , Vol. 339, pp. 394-397.  |
| EXAMINER   |  | DATE CONSIDERED  |

|  |  |  |
|--|--|--|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>  |  |
| C32  | Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , Vol. 335, pp. 370-372.   |  |
| C33  | Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , Vol. 159, No. 1, pp. 351-358. |  |
| C34  | Cheon et al. (1994) "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> 91: 989-993.  |  |
| C35  | Cohen, S. L. et al., (August 15, 1996), "Human leptin characterization," <u>Nature</u> , Vol. 382, p. 589.   |  |
| C36  | Cole et al. (1997) "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , Vol. 159, pp. 3613-3621.   |  |
| C37  | Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , Vol. 56, pp. 2531-2534.  |  |
| C38  | D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91, pp. 4082-4085.   |  |
| C39  | D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , Vol. 176, pp. 1387-1398.   |  |
| C40  | Ding et al., (September 1988), "Zinc-Dependent Dimers Observed in Crystals of Human Edostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , Vol. 95, No. 18, pp. 10443-10448.  |  |
| C41  | Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , Vol. 161, pp. 156-166.   |  |
| C42  | Eisenthal, (1990) "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> Vol. 31, pp. 342-348.   |  |
| C43  | Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , Vol. 146, pp. 2446-2452.  |  |
| C44  | Friedman, J. M. et al., (October 22, 1998). "Leptin and the regulation of body weight in mammals," <u>Nature</u> , Vol. 395, pp. 763-770.  |  |
| C45  | Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils", <u>Science</u> , Vol. 226, pp. 1339-134.   |  |
| C46  | Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses" <u>Annu. Rev. Immunol.</u> , Vol. 16, pp. 495-521.  |  |
| C47  | Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist" <u>Eur. J. Immunol.</u> , Vol. 25, pp. 200-206.   |  |
| <b>EXAMINER</b>  |  | <b>DATE CONSIDERED</b>   |

RECEIVED  
MAY 05 2003  
TECH CENTER  
1600/2900

|  |   |   |
|--|---|---|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |   | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999      GROUP: 1646 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>   |   |
| C48  | Gillies et al. (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> Vol. 1, No. 1, pp. 47-54.                               |   |
| C49  | Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , Vol. 125, pp. 191-202.  |   |
| C50  | Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , Vol. 89, pp. 1428-1432.   |   |
| C51  | Gillies et al., (1989), "Expression of Human Anti-Tetanus toxoid antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , Vol. 7, pp. 799-804.  |   |
| C52  | Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , Vol. 120, No. 6, pp. 2027-2032.  |   |
| C53  | Goeddel et al., (1986), "Tumor Necrosis Factors; Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.   |   |
| C54  | Gren et al., (1983), "A New Type of Leukocytic Interferon,".. <u>Dokl. Biochem.</u> , Vol. 269, pp. 91-95.  |   |
| C55  | Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , Vol. 73, No. 8, pp. 2081-2805.         |   |
| C56  | Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> Vol. 45, pp. 146-148.  |   |
| C57  | Harris et al., "Therapeutic Antibodies - the Coming of Age" <u>Tibtech</u> , 11:42-44 (Feb. 1993).  |   |
| C58  | Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , Vol. 11, Issue 6, pp. 629-636. |   |
| C59  | He et al. (1998) "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> 1029-1035.  |   |
| C60  | Heijnen et al. (1996) "Antigen Targeting to Myeloid-specific Human FcYRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , Vol. 97, No. 2, pp. 331-338.                                      |   |
| C61  | Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers" <u>In Vivo Biology of IL-12 p40 Homodimer</u> ," <u>Journal of Immunology</u> , Vol. 158, pp. 4381-4388.  |   |
| <b>EXAMINER</b>  |   | <b>DATE CONSIDERED</b>  |

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

|  |  |  |
|--|--|--|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999 |
| <b>EXAM. INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>  |  |
| C62  | Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 83, No. 18, pp. 7059-7063.  |  |
| C63  | Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , Vol. 3, pp. 31-58.   |  |
| C64  | Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , Vol. 7, No. 2, pp. 159-167.                                       |  |
| C65  | Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1/5 Å Resolution," <u>EMBO Journal</u> , Vol. 17, No. 6, pp. 1656-1664.  |  |
| C66  | Holden, et al. (2001) "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents." <u>Proceedings of the American Association for Cancer Research</u> , Vol. 42, p. 683.   |  |
| C67  | Holden, et al. (2001) "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents" <u>Clinical Cancer Research</u> ; Vol. 7, No. 9, pp. 2862-2869.  |  |
| C68  | Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , Vol. 1096, No. 4, pp. :345-354 (Abstract). |  |
| C69  | Hoogenboom et al., (1991), "Constriction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , Vol. 28, No. 9, pp. 1027-1037  |  |
| C70  | Huck et al. (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14, No. 4, pp. 1779-1789.   |  |
| C71  | Huse et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , Vol. 246, pp. 1275-1281.   |  |
| C72  | Ingber et al. (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , Vol. 348, pp. 555-557.  |  |
| C73  | Jones et al., (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , Vol. 321, No. 6069, pp. 522-525.   |  |
| C74  | Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 4479-4483.                                      |  |
| C75  | Junghans et al. (1996) "The protection receptor of IgG catabolism is the B2-micorgobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, No. 11, pp. 5512-5516.   |  |
| C76  | Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88, pp. 11120-11123.  |  |
| <b>EXAMINER</b>  |  | <b>DATE CONSIDERED</b>   |

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

|  |  |  |
|--|--|--|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>  |  |
| C77  | Kappel, et al. (1992) "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> 3:548-553  |  |
| C78  | Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc $\lambda$ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , Vol. 160, No. 6, pp. 1686-1701. |  |
| C79  | Kendra et al., (1999), "Pharmacokinetics and stability of the ch 14.18-interleukin-2 fusion protein in mice," <u>Cancer Immunol. Immunotherapy</u> , Vol. 48, pp. 219-229.   |  |
| C80  | Kim, et al. (1999) "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV" <u>Journal of Interferon and Cytokine Research</u> , Vol. 19, pp. 77-84.   |  |
| C81  | Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 81, 7922-7926.   |  |
| C82  | Kuo, et al. (2001) "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , Vol. 152, No. 6, pp. 1233-1246.  |  |
| C83  | LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , Vol. 268, No. 31, pp. 23311-23317.  |  |
| C84  | Lazar et al., (1988), "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> Vol. 8, No. 3, pp. 1247-1252.                                    |  |
| C85  | LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , Vol. 51, pp. 2694-2698.  |  |
| C86  | Linsley et al. (1991) "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , Vol. 174, No. 3, pp. 561-569.  |  |
| C87  | Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , Vol. 239, pp. 395-398.   |  |
| C88  | Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 82, pp. 8648-8652.   |  |
| C89  | Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , Vol. 92, No. 10, pp. 3730-3736.                               |  |
| C90  | Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells" <u>Protein Engineering</u> , Vol. 11, No. 6, pp. 495-500.  |  |
| C91  | Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , Vol. 91, No. 5, pp. 1706-1715.  |  |
| <b>EXAMINER</b>  |  | <b>DATE CONSIDERED</b>   |

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

|  |   |  |
|--|---|--|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |   | <b>ATTORNEY DOCKET NO.:</b> LEX-003<br><b>APPLICANT(S):</b> Gillies et al.<br><b>SERIAL NO.:</b> 09/256,156<br><b>FILING DATE:</b> February 24, 1999 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>   |  |
| C92  | Lode et al., (1999), "Synergy between an antiangiogenic integrin $\alpha_v$ antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 1591-1596.              |  |
| C93  | Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , Vol. 29, No. 2, pp. 117-120.   |  |
| C94  | Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 8591-8596.   |  |
| C95  | Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDE-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , Vol. 84, No. 8, pp. 2457-2466.             |  |
| C96  | Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> Vol. 25, pp. 137-146.                                |  |
| C97  | Medesan et al. (1997) "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1 <sup>1</sup> ," <u>Journal Immunology</u> , Vol. 158, No. 5, pp. 2211-2217.   |  |
| C98  | Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , Vol. 57, pp. 2890-2895.  |  |
| C99  | Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> Vol. 7, pp. 145-173.   |  |
| C100   | Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related $\alpha$ -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83, pp. 8258-8262. |  |
| C101   | Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , pp. 123-140.  |  |
| C102   | Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , Vol. 13, No. 17, pp. 6361-6373.   |  |
| C103   | Neuberger, et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , Vol. 312, pp. 604-608.   |  |
| C104   | O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , Vol. 79, pp. 315-328.   |  |
| C105   | O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , Vol. 2, No. 6, pp. 689-692.  |  |
| C106   | O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , Vol. 88 pp. 277-285.   |  |
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b>  |  |

RECEIVED  
 MAY 05 2003  
 TECH CENTER  
 1600/2900

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

|  |  |   |
|--|--|---|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999<br>GROUP: 1646 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>  |   |
| C107   | Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins", <u>Journal of Biological Chemistry</u> , Vol. 264, No. 26, pp. 15157-15160.  |   |
| C108   | Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , Vol. 6, pp. 407-438.   |   |
| C109   | Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , Vol. 163, pp. 166-178.   |   |
| C110   | Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal Immunology</u> , Vol. 142, No. 10, pp. 3662-3667.  |   |
| C111   | Putzer et al. (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , Vol. 94, pp. 10889-10894.   |   |
| C112   | Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , Vol. 7. Suppl. 2, pp. S99-S106.  |   |
| C113   | Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , Vol. 343, pp. 1177-1183.   |   |
| C114   | Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition.  |   |
| C115   | Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , Vol. 9, No. 2, pp. 58-62.   |   |
| C116   | Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> 2, Vol. 2, No. 3, pp. 159-173.  |   |
| C117   | Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , Vol. 46, pp. 4701-4705.  |   |
| C118   | Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , Vol. 17, No. 15, pp. 4249-4256.   |   |
| C119   | Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 84, pp. 6904-6908.   |   |
| C120   | Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , Vol. 148, No. 11, pp. 3433-3340.   |   |
| C121   | Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 85, No. 13, pp. 4842-4846.  |   |
| C122   | Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG mediates cytotoxicity by Human Monocytes that is enhanced by interferon- $\lambda$ and is not blocked by human IgG," <u>Journal of Immunology</u> , Vol. 137, No. 11, pp. 3378-3382. |   |
| <b>EXAMINER</b>  |  | <b>DATE CONSIDERED</b>  |

|  |  |  |
|--|--|--|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |  | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>  |  |
| C123   | Shiff et al., (1995), "Sulindac Sulfide, an Asprin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , Vol. 96, pp. 491-503. |  |
| C124   | Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, pp. 5322-5326.         |  |
| C125   | Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , Vol. 57, pp. 1329-1334.  |  |
| C126   | Stevenson et al., (1997), "Conjugation of Human Fcγ in Closed-Hinge or Open-Hinge Configuration to Fab'γ and Analogous Ligands," <u>Journal of Immunology</u> , Vol. 158, pp. 2242-2250.   |  |
| C127   | Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , Vol. 302, pp. 305-309.  |  |
| C128   | Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , Vol. 143, No. 8, pp. 2595-2601.            |  |
| C129   | Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , Vol. 178, No. 2, pp. 661-667.   |  |
| C130   | Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , Vol. 57, pp. 920-925.   |  |
| C131   | <u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 <sup>th</sup> ed. 1999).   |  |
| C132   | Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , Vol. 48, No. 5, pp. 1119-1123  |  |
| C133   | Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , Vol. 242, pp. 1166-1168   |  |
| C134   | Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , Vol. 84, pp. 4008-4027.                   |  |
| C135   | Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , Vol. 56, pp. 467-470.   |  |
| C136   | Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , Vol. 44, pp. 681-687.  |  |
| C137   | Verhoeven et al. (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> 239:1534-1536.   |  |
| <b>EXAMINER</b>  |  | <b>DATE CONSIDERED</b>   |

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900

|  |   |  |
|--|---|--|
| <b>FORM PTO - 1449</b><br><b>SUPPLEMENTAL INFORMATION</b><br><b>DISCLOSURE STATEMENT</b> |   | ATTORNEY DOCKET NO.: LEX-003<br>APPLICANT(S): Gillies et al.<br>SERIAL NO.: 09/256,156<br>FILING DATE: February 24, 1999 |
| <b>EXAM.<br/>INIT.</b>   | <b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>   |  |
| C138   | Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein", <u>Protein Engineering</u> , Vol. 1, No. 6, pp. 493-498. |  |
| C139   | Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , Vol. 43, pp. 319-324.   |  |
| C140   | Wooley et al. (1993) "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>J. Immunol.</u> 151: 6602-6607.  |  |
| C141   | Wu et al., (July 1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin", <u>Biochemical and Biophysical Research Communications</u> , Vol. 236, No. 3, pp. 651-654.   |  |
| C142   | Xiang et al. (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , Vol. 57, pp. 4948-4955.   |  |
| <b>EXAMINER</b>  | <b>DATE CONSIDERED</b>  |  |

2614877

RECEIVED  
MAY 05 2003  
TECH CENTER 1600/2900